Products currently under clinical development (continued)  (as of August 1, 2014) Code No.  Generic Name Classification Target Disease Phase 1 Phase 2 Phase 3 Filed Area Dosage  Form Origin Remarks Neuroscience FK949E quetiapine Serotonin/  dopamine antagonist Depressive episode in bipolar  disorders Japan Oral AstraZeneca New indication/  New formulation* 1 NGX-4010 capsaicin TRPV1 agonist Peripheral diabetic  neuropathy Europe Patch NeurogesX New  indication* 2 ASP8477 Inhibition of central  sensitization Neuropathic pain Europe Oral In-house ASP9226 Neuropathic pain Oral In-house ASP3662 Alzheimer’s disease Oral In-house ASP7962 Osteoarthritis, Chronic low  back pain Oral In-house ASP3700 Osteoarthritis Oral In-house DM Complications and Kidney Diseases, Others nateglinide Fast acting insulin  secretion enhancer Type 2 diabetes Combination with DPP-4  inhibitor Japan Oral Ajinomoto New  indication* 1 (14/07) YM060 ramosetron 5-HT3 receptor  antagonist Irritable bowel syndrome with  diarrhea in female patients Japan Oral In-house New  indication* 1 (14/07) ASP1517 (FG-4592) roxadustat HIF stabilizer Anemia associated with  chronic kidney disease in  patients not on dialysis and  on dialysis Europe Oral FibroGen Japan YM533 beraprost sodium Prostacyclin receptor stimulator Chronic renal failure (primary, nephrosclerosis) Japan/ Asia Oral Toray New  indication* 1 ASP1585 (AMG 223) bixalomer Amine-functional  polymer Hyperphosphatemia in  patients not on dialysis with  chronic kidney disease Japan Oral Amgen New  indication* 1 Hyperphosphatemia in patients  on dialysis with chronic kidney  disease (granule formulation) Japan Oral New  formulation* 1 Bioequivalence study AMG 785 romosozumab Anti-Sclerostin  monoclonal  antibody Osteoporosis Japan Injection Amgen (co-development  with Amgen  Astellas) * 1 AMG 145 evolocumab Anti-PCSK-9 monoclonal  antibody Hyperlipidemia Japan Injection Amgen (co-development  with Amgen  Astellas) * 1 YM311 (FG-2216) HIF stabilizer Renal anemia Europe Oral FibroGen Japan ASP1707 GnRH antagonist Endometriosis Europe/ Japan Oral In-house ASP0456 linaclotide Guanylate cyclase  type-C receptor agonist Irritable bowel syndrome Japan Oral Ironwood * 1 ASP7991 Calcium-sensing  receptor activator Secondary  hyperparathyroidism Japan Oral In-house * 1 ASP8232 Diabetic nephropathy Oral In-house ASP3325 Hyperphosphatemia Oral In-house CK-2127107 Skeletal muscle disease (non- neuromuscular indications) Oral Cytokinetics ASP7657 Diabetic nephropathy Oral In-house *1 Local development (Japan) *2 Local development (Europe) Astellas Pharma Inc.  _ Annual Report 2014 40